Insights

Innovative Therapeutics Merus specializes in developing bispecific antibody therapies, particularly the Biclonics® platform, which offers multi-faceted cancer treatment approaches. This positions the company as a leader in next-generation oncology treatments, providing opportunities to sell advanced biotherapeutic solutions and diagnostic tools tailored for complex cancer therapies.

Strategic Collaborations Recent partnerships with companies like Partner Therapeutics and Foundation Medicine highlight Merus's focus on expanding its treatment pipeline and diagnostic capabilities. These collaborations create openings for sales of companion diagnostics, platform licensing, and customized research services aligned with Merus’s innovative therapies.

Growing Market Presence Merus is actively engaged in clinical development and presentation at major conferences, indicating a strong market footprint and visibility among oncology stakeholders. Engagement with leading biotech and pharma companies offers multiple channels for strategic partnerships and co-commercialization opportunities.

Market Focused Platform By developing RNA-based diagnostics and targeted therapies like Zeno for specific tumor types, Merus is targeting highly specialized niches within oncology. Selling complementary diagnostic platforms, targeted populations, and treatment adjuncts presents numerous opportunities for market penetration and revenue growth.

Similar companies to Merus

Merus Tech Stack

Merus uses 8 technology products and services including SAS, Google Hosted Libraries, oEmbed, and more. Explore Merus's tech stack below.

  • SAS
    Business Intelligence
  • Google Hosted Libraries
    Content Delivery Network
  • oEmbed
    Dev Tools
  • TweenMax
    Javascript Frameworks
  • New Relic
    Real User Monitoring
  • reCAPTCHA
    Security
  • HSTS
    Security
  • ExactMetrics
    Web Platform Extensions

Media & News

Merus's Email Address Formats

Merus uses at least 1 format(s):
Merus Email FormatsExamplePercentage
F.Last@merus.nlJ.Doe@merus.nl
73%
First.Last@merus.nlJohn.Doe@merus.nl
14%
First_Last@merus.nlJohn_Doe@merus.nl
13%

Frequently Asked Questions

Where is Merus's headquarters located?

Minus sign iconPlus sign icon
Merus's main headquarters is located at 62 Yalelaan Utrecht, Utrecht 3584 cm Netherlands. The company has employees across 2 continents, including EuropeNorth America.

What is Merus's phone number?

Minus sign iconPlus sign icon
You can contact Merus's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Merus's stock symbol?

Minus sign iconPlus sign icon
Merus is a publicly traded company; the company's stock symbol is MRUS.

What is Merus's official website and social media links?

Minus sign iconPlus sign icon
Merus's official website is merus.nl and has social profiles on LinkedInCrunchbase.

What is Merus's SIC code NAICS code?

Minus sign iconPlus sign icon
Merus's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Merus have currently?

Minus sign iconPlus sign icon
As of March 2026, Merus has approximately 287 employees across 2 continents, including EuropeNorth America. Key team members include Chief Executive Officer: M. C.Cfo: G. P.Cto: J. D. K.. Explore Merus's employee directory with LeadIQ.

What industry does Merus belong to?

Minus sign iconPlus sign icon
Merus operates in the Biotechnology Research industry.

What technology does Merus use?

Minus sign iconPlus sign icon
Merus's tech stack includes SASGoogle Hosted LibrariesoEmbedTweenMaxNew RelicreCAPTCHAHSTSExactMetrics.

What is Merus's email format?

Minus sign iconPlus sign icon
Merus's email format typically follows the pattern of F.Last@merus.nl. Find more Merus email formats with LeadIQ.

How much funding has Merus raised to date?

Minus sign iconPlus sign icon
As of March 2026, Merus has raised $300M in funding. The last funding round occurred on Jun 03, 2025 for $300M.

Merus

Biotechnology ResearchUtrecht, Netherlands201-500 Employees

Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl
Read our Community Guidelines: https://merus.nl/community-guidelines/

Section iconCompany Overview

Headquarters
62 Yalelaan Utrecht, Utrecht 3584 cm Netherlands
Phone number
Website
merus.nl
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
MRUS
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
201-500

Section iconFunding & Financials

  • $300M

    Merus has raised a total of $300M of funding over 12 rounds. Their latest funding round was raised on Jun 03, 2025 in the amount of $300M.

  • $25M$50M

    Merus's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $300M

    Merus has raised a total of $300M of funding over 12 rounds. Their latest funding round was raised on Jun 03, 2025 in the amount of $300M.

  • $25M$50M

    Merus's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.